Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
Clinical role
Measurement or quantification
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.
Who uses it?Intended users: Clinical specialists, physicians, and other licensed practitioners; non-physician results must be validated by the responsible physician.
What does the software produce?Output: Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.
What is its most important limitation?Key limitation: Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.
Clinical takeaway. Clinical role: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
Evidence takeaway. Evidence from the reviewed source record: FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.
Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.
FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.
Validation Study Comparing Artificial Intelligence for Fully Automatic Aortic Aneurysms Segmentation and Diameter Measurements on Contrast and Noncontrast Enhanced Computed Tomography
DesignSingle-center retrospective comparative study
Population120 CT scans, equally divided between CTA and noncontrast CT, in aneurysm-repair and control cases; two vascular surgeons provided semiautomatic comparison measurements.
Scopeproduct family
Tested versionPRAEVAorta2; exact build and K243859 equivalence not established
Samplen=120
Sites1
IndependenceIndependence not established
PMID:40480487 · DOI:10.1016/j.avsg.2025.05.045
Abstract and affiliations reviewed; a Nurea-affiliated author is listed. Numeric results are not transferred to K243859. This is scan count, not unique-patient count.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Server software accessed through APIs, with a web client, gateway/PACS client, integrating solution, or marketplace; PDF, JSON, DICOM SC, and DICOM GSPS outputs.
Scope: Exact FDA submission. Specific PACS versions and supported transactions require local confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes PRAEVAorta 2 as server software usable through APIs that is cloud based or can be installed on premises, with a client software (such as a web client) providing the interface to send images and receive results. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "This software is cloud based or can be installed on premises. PRAEVAorta®2 is a server software usable through APIs." … "The client aims to provide a user interface to send images and receive the analysis results. It can either be a web client". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes PRAEVAorta 2 as server software usable through APIs that is cloud based or can be installed on premises, with a client software (such as a web client) providing the interface to send images and receive results. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "This software is cloud based or can be installed on premises. PRAEVAorta®2 is a server software usable through APIs." … "The client aims to provide a user interface to send images and receive the analysis results. It can either be a web client". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Server software accessed through APIs, with a web client, gateway/PACS client, integrating solution, or marketplace; PDF, JSON, DICOM SC, and DICOM GSPS outputs.
Exact FDA submission
Checked 2026-09-05
Specific PACS versions and supported transactions require local confirmation.
Nurea describes automatic arterial reconstruction integrated with PACS, workstations, and imaging software, including lumen/thrombus differentiation and longitudinal follow-up.
product family · checked 2026-09-05
Current product-family description. Local compatibility and any features beyond the FDA indications require separate confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
28Fields reviewed
12Source classes checked
2Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads
All stored metadata screened. PMID 40480487 abstract supports a contextual PRAEVAorta2 study, without exact-build linkage. PMID 41321026 concerns carotid-lesion segmentation; exact aortic-product applicability not established and no results promoted. Live registry content identifies NCT05287828 and NCT05920317 as Nurea/PRAEVAorta-family studies; no posted results or exact K243859 build linkage were established, so neither is promoted as exact-submission clinical performance. The current discovery snapshot contains 2 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, vendor product page, literature index, peer reviewed literature, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The reviewed official product page offers a demo without scoped pricing. Licensing, processing volume, client/integration costs, support, and cloud/on-premises terms require quotation; procurement research is incomplete.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Nurea PRAEVAorta reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
FDA functional data-security testing and general vendor language do not establish a current scoped attestation, hosting region, retention policy, or access-control configuration.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Training of reference readers in the FDA study is not a customer onboarding commitment. Current user training and support terms remain unverified.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Local acceptance, output correction, update control, and incident escalation require vendor and site documentation.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.